What is the 13F Pro Quality Score for CLDX?

13F Pro ranks Celldex Therapeutics, Inc. (CLDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLDX's current score at https://13fpro.ai/company/CLDX (free sign-up required for the full ranking).

Where does 13F Pro source CLDX data?

All Celldex Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Celldex Therapeutics, Inc. files with the SEC under CIK 744218. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLDX in?

Celldex Therapeutics, Inc. (CLDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLDX research updated on 13F Pro?

CLDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Celldex Therapeutics, Inc.(CLDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 744218 CLDX stock profile & AI dashboard →

13F Pro Quality Score

8.4/100

Rank #2,930 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

1.8/100

Profitability

0.4/100

Balance Sheet

4.9/100

Earnings Quality

24.0/100

Free Cash Flow

0.3/100

Institutional Flow

95.3/100

Revenue Scale

0.5/100

Dilution Risk

0.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CLDX Scores 8/100

exact factor attribution · 2026-09-11

CLDX's composite is driven by institutional flow, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.3 pts

95th pct

Earnings growth

-2.3 pts

4th pct

Shareholder dilution

-2.5 pts

0th pct

Earnings quality

-2.6 pts

24th pct

Capital efficiency

-4.5 pts

5th pct

Scale

-7.4 pts

1th pct

Profitability

-7.4 pts

0th pct

Free cash flow

-7.5 pts

0th pct

Revenue growth

-9.6 pts

2th pct

Latest change (2026-08-06): 13 → 3 · ↓ Profit margin 30→0; ↓ Capital efficiency 30→5

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in CLDX

Events flagged as statistical outliers against CLDX's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-06
CLDX quality score dropped 10 points (13→3) on a new filing
View source filing →

CLDX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Celldex Therapeutics, Inc. (CLDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLDX at 8.4/100 on a 32-signal composite quality model, placing it at rank #2,930 of 2,961 stocks — the bottom half of the AI-ranked universe. CLDX scores in the top quartile across institutional flow (95.3). Areas of concern include free cash flow (0.3) and profitability (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Celldex Therapeutics, Inc. reports quarterly revenue of $22.0K, net income of $-73.5M, free cash flow of $-60.6M. Top institutional holders of CLDX by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, BlackRock, Kynam Capital Management, based on the most recent SEC filings. CLDX trades on the Nasdaq exchange and files with the SEC under CIK 744218. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celldex Therapeutics, Inc. directly from SEC EDGAR. Celldex Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 40 since 2021, currently 8.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$22.0K

Net Income

Q2 2026

$-73.5M

Free Cash Flow

Q2 2026

$-60.6M

ROIC

Q2 2026

-45.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-78.0% YoY

$1.5MFY 2025

FY22 $2.4MFY23 $6.9MFY24 $7.0MFY25 $1.5M

Net Income

-63.9% YoY

$-258.8MFY 2025

FY22 $-112.3MFY23 $-141.4MFY24 $-157.9MFY25 $-258.8M

Operating Income

-47.3% YoY

$-287.4MFY 2025

FY22 $-115.2MFY23 $-154.5MFY24 $-195.1MFY25 $-287.4M

EPS (Diluted)

-59.2% YoY

$-3.90FY 2025

FY22 $-2.40FY23 $-2.92FY24 $-2.45FY25 $-3.90

Total Assets

-26.4% YoY

$583.0MFY 2025

FY22 $352.7MFY23 $465.6MFY24 $792.3MFY25 $583.0M

Op. Cash Flow

-33.7% YoY

$-210.9MFY 2025

FY22 $-103.7MFY23 $-107.3MFY24 $-157.8MFY25 $-210.9M

Free Cash Flow

-33.8% YoY

$-213.7MFY 2025

FY22 $-105.6MFY23 $-109.1MFY24 $-159.7MFY25 $-213.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.5M -78.0%	$7.0M +2.0%	$6.9M +192.0%	$2.4M -49.3%	$4.7M -37.3%	$7.4M
Net Income	$-258.8M -63.9%	$-157.9M -11.6%	$-141.4M -25.9%	$-112.3M -59.3%	$-70.5M	—
Operating Income	$-287.4M -47.3%	$-195.1M -26.2%	$-154.5M -34.1%	$-115.2M -61.7%	$-71.2M -12.5%	$-63.4M
EPS (Diluted)	$-3.90 -59.2%	$-2.45 +16.1%	$-2.92 -21.7%	$-2.40 -46.3%	$-1.64 +18.8%	$-2.02
Total Assets	$583.0M -26.4%	$792.3M +70.2%	$465.6M +32.0%	$352.7M -20.7%	$444.7M +88.5%	$235.8M
Operating Cash Flow	$-210.9M -33.7%	$-157.8M -47.1%	$-107.3M -3.4%	$-103.7M -70.3%	$-60.9M -50.7%	$-40.4M
Free Cash Flow	$-213.7M -33.8%	$-159.7M -46.4%	$-109.1M -3.4%	$-105.6M -69.8%	$-62.2M -48.2%	$-42.0M

Get alerted when CLDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Celldex Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLDX

WELLINGTON MANAGEMENT GROUP LLP
$355.1M9,543,671 sh
BlackRock, Inc.
$260.6M7,002,530 sh
Kynam Capital Management, LP
$198.1M5,322,908 sh
PRICE T ROWE ASSOCIATES INC /MD/
$174.3M4,685,223 sh
STATE STREET CORP
$145.1M3,900,427 sh
FMR LLC
$138.5M3,722,888 sh
VANGUARD CAPITAL MANAGEMENT LLC
$128.9M3,464,831 sh
Deep Track Capital, LP
$109.4M2,939,151 sh
Logos Global Management LP
$78.1M2,100,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$75.3M2,022,226 sh

Fund	Value	Shares
WELLINGTON MANAGEMENT GROUP LLP	$355.1M	9,543,671
BlackRock, Inc.	$260.6M	7,002,530
Kynam Capital Management, LP	$198.1M	5,322,908
PRICE T ROWE ASSOCIATES INC /MD/	$174.3M	4,685,223
STATE STREET CORP	$145.1M	3,900,427
FMR LLC	$138.5M	3,722,888
VANGUARD CAPITAL MANAGEMENT LLC	$128.9M	3,464,831
Deep Track Capital, LP	$109.4M	2,939,151
Logos Global Management LP	$78.1M	2,100,000
GEODE CAPITAL MANAGEMENT, LLC	$75.3M	2,022,226

Companies Similar to CLDX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

RLAY

Relay Therapeutics, Inc.

AI score

Very similar · 24 shared holders

Kynam Capital Management, LP Commodore Capital LP Bellevue Group AG

SLN

Silence Therapeutics plc

AI score

Very similar · 12 shared holders

Redmile Group, LLC TFG Asset Management GP Ltd 5AM Venture Management, LLC

CTMX

CytomX Therapeutics, Inc.

AI score

Very similar · 16 shared holders

Kynam Capital Management, LP BAKER BROS. ADVISORS LP Elmind Capital, LP

RCUS

Arcus Biosciences, Inc.

AI score

Very similar · 20 shared holders

BAKER BROS. ADVISORS LP Logos Global Management LP Candriam S.C.A.

NKTR

NEKTAR THERAPEUTICS

AI score

Very similar · 18 shared holders

Deep Track Capital, LP ADAR1 Capital Management, LLC BRAIDWELL LP

ROIV

Roivant Sciences Ltd.

AI score

Similar quality profile · 18 shared holders

BAKER BROS. ADVISORS LP Affinity Asset Advisors, LLC ADAR1 Capital Management, LLC

ALMS

ALUMIS INC.

AI score

Similar quality profile · 17 shared holders

Deep Track Capital, LP BAKER BROS. ADVISORS LP Foresite Capital Management VI LLC

STRO

SUTRO BIOPHARMA, INC.

AI score

Similar quality profile · 8 shared holders

Kynam Capital Management, LP Affinity Asset Advisors, LLC EVENTIDE ASSET MANAGEMENT, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLDX on your watchlist

Track score changes the day Celldex Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLDX a good stock to buy?

13F Pro's AI-powered analysis of Celldex Therapeutics, Inc. (CLDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLDX are available on the CLDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CLDX is classified as a mid company.

Which hedge funds own CLDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Celldex Therapeutics, Inc.'s investment landscape.